华润医药(03320.HK)旗下人凝血因子IX获内地药物临床试验批准通知书

阿斯达克财经
Feb 25

华润医药(03320.HK) 公布,旗下华润博雅生物制药集团收到国家药品监督管理局颁发的人凝血因子IX《药物临床试验批准通知书》。该产品用于凝血因子IX缺乏症(血友病B)患者的出血治疗。(ca/j)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-25 12:25。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10